Nektar Therapeutics

NKTR Healthcare Biotechnology

Nektar Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $55.2 million, down 43.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.34%, EPS grew 58.3% and free cash flow fell 65.7%, each against the same quarter a year earlier.

35.78 1.94 −5.14%
Market cap
$1.3B
P/E
0.0×
Fwd P/E
−6.3×
Dividend yield
—
F-score
3/9
Altman Z
−17.07
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 3 4 4
ROE
(180.24%) (217.94%) (53.60%) (35.75%)
ROA
(39.63%) (56.17%) (31.01%) (24.12%)
ROIC
0.00% 0.00% (1,105.34%) (40.20%)
Return on Tangible Assets
(55.42%) (76.39%) (29.75%) (23.51%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(10.05) (12.37) (8.24) (7.08)
Free Cash Flow
(190.35) (208.68) (203.94) (234.03)
Capital Expenditures
(0.61) (0.17) (0.19) (0.24)
Other line items
Cash ROIC
(53.58%) (62.18%) (17.81%) (14.74%)
Accounts Receivable Turnover
0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
185.88% 212.43% 220.25% 241.39%
Selling, General and Administrative Expense of Revenue
119.21% 124.34% 103.83% 97.93%
Share Based Compensation of Revenue
24.38% 22.90% 21.76% 21.95%
Interest Coverage
(3.69) (5.35) (4.62) (4.54)
Operating CF/Net income
1.57 1.27 1.29 1.49
Depreciation/Fixed assets
1.86 0.50 0.00 0.00
Capex/Depreciation
(0.12) (0.17) (0.45) 0.10
Revenue per Share
3.30 3.27 2.25 1.65
Operating CF per Share
(10.01) (12.36) (8.24) (7.07)
Capex per Share
(0.03) (0.01) (0.01) (0.01)
Capex to Sales
0.01 0.00 0.00 0.00

Fold the line items

Columns are period end dates